Next Science Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXSCF research report →
Price Chart
About the company
Next Science Limited operates as a medical technology firm, dedicated to the research, development, and commercialization of innovative solutions aimed at mitigating the detrimental effects of biofilms on human health. The company serves markets in both the United States and Australia, building its product portfolio on its proprietary Xbio Technology platform. Among its key offerings are: SURGX: An antimicrobial gel employed for managing surgical infections.
- CEO
- Matthew Franco Myntti
- IPO
- 2021
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on NXSCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $292.63K
- P/E
- -2.78
- PEG
- -0.06
- P/S
- 1.29
- P/B
- 8.55
- EV/EBITDA
- -3.36
- Div Yield
- 100.00%
- Gross Margin
- 80.83%
- Op Margin
- -45.16%
- Net Margin
- -46.40%
- ROE
- -130.18%
- ROIC
- -165.73%
Latest fiscal year · YoY change
- Revenue
- $22.82M+2.9%
- Gross Profit
- $18.44M+13.6%
- Op Income
- $-10,304,109
- Net Income
- $-10,586,018+56.8%
- EPS
- $-0.04+47.8%
- OCF Growth
- +47.1%
- FCF Growth
- +46.4%
- 52W High
- $0.11
- 52W Low
- $0.00
- 50D MA
- $0.06
- 200D MA
- $0.06
- Beta
- 1.69
- RSI (14)
- 23
- Avg Volume
- 4.23K
No earnings-call transcripts are available for NXSCF yet.
- Free Float
- 47.6%
- Shares Outstanding
- 292.63M
- Float Shares
- 139.25M
Our NXSCF coverage
Recent articles, reports, and earnings notes.
No research on NXSCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXSCF report →